➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKesson
Boehringer Ingelheim
AstraZeneca
Merck

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Volitinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Volitinib?

Volitinib is an investigational drug.

There have been 25 clinical trials for Volitinib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 25th 2017.

The most common disease conditions in clinical trials are Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, and Carcinoma, Renal Cell. The leading clinical trial sponsors are AstraZeneca, Hutchison Medipharma Limited, and National Cancer Institute (NCI).

There are six US patents protecting this investigational drug and one hundred and eight international patents.

Recent Clinical Trials for Volitinib
TitleSponsorPhase
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCAstraZenecaPhase 2
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the BodyParexelPhase 1
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the BodyAstraZenecaPhase 1

See all Volitinib clinical trials

Clinical Trial Summary for Volitinib

Top disease conditions for Volitinib
Top clinical trial sponsors for Volitinib

See all Volitinib clinical trials

US Patents for Volitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Volitinib   Start Trial Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor Hutchison Medipharma Limited (Pudong, Shanghai, CN)   Start Trial
Volitinib   Start Trial Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor Hutchison Medipharma Limited (Pudong, Shanghai, CN)   Start Trial
Volitinib   Start Trial Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor AstraZeneca AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKesson
Boehringer Ingelheim
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.